Can boldenone undecylenate be effectively combined with HGH in the same cycle?

Yes — boldenone undecylenate and HGH can be combined effectively because they act through entirely separate receptor pathways. Boldenone engages the androgen receptor to drive nitrogen retention and contractile protein synthesis, while HGH activates the GH receptor and JAK-STAT cascade to raise IGF-1 and stimulate collagen remodelling. The two mechanisms stack additively without pharmacological redundancy.

What specific synergies does the boldenone and growth hormone combination produce in terms of body composition?

The primary synergy is a clean lean-mass outcome: boldenone supplies androgen-receptor-mediated muscle protein accrual and haematocrit support, while HGH accelerates tendon and ligament collagen synthesis to keep connective tissue resilient under progressive overload. Because boldenone aromatises at roughly half the rate of testosterone — confirmed in comparative conversion assays — estrogenic fluid does not mask the recompositioning driven by the growth hormone component.

How should an HGH and boldenone undecylenate stack be structured in terms of timing and duration?

HGH protocols typically require 16–24 weeks before structural tissue remodelling is measurable, so boldenone undecylenate should be run for a minimum of 16 weeks to align with that window. A practical approach starts HGH first by two to four weeks to establish baseline IGF-1 elevation, then introduces boldenone at 250–400 mg weekly. Blood panels covering IGF-1, haematocrit, and hormonal markers should be drawn at eight-week intervals throughout.

Why are single-dose 1 ml ampoules preferable to multi-dose vials for a long HGH-combination cycle?

Single-dose ampoules eliminate the cumulative contamination risk that builds with repeated needle puncture through a rubber septum over a 20-plus-week cycle. Each ampoule is hermetically sealed at manufacture and opened only once, guaranteeing sterility at the point of injection regardless of how many weeks into the protocol the user is. This is particularly relevant when cycle duration extends beyond 12 weeks.

How should Omega Meds Equipoise 10x1ml ampoules be stored to maintain potency across a multi-month stack?

Store ampoules between 15 °C and 25 °C, away from direct light and heat sources. Do not refrigerate, as temperature cycling can cause the oil vehicle to precipitate. Unopened ampoules remain stable until the printed expiry date when stored correctly. Once an ampoule is cracked open it must be used in a single injection session — partial-use storage is not applicable to this single-dose format. (2) angle_used

Back in Stock

Omega Meds

Equipoise 250mg/ml 10x1ml Ampullen by Omega Meds

Name: Equipoise 250mg/ml 10x1ml Ampoules by Omega Meds
Brand: Omega Meds
SKU: INJ-BOLD-OME-250-017
Price: 47.00 EUR
Availability: InStock

Omega Meds Equipoise delivers boldenone undecylenate at 250 mg/ml in ten individually sealed 1 ml glass ampoules, purpose-suited to athletes building lean-tissue protocols around exogenous growth hormone. The long-acting undecylenate ester provides a sustained anabolic environment that complements HGH's collagen-synthesis and IGF-1-mediated hypertrophy signals without the estrogenic interference associated with higher-aromatising androgens. Potency and sterility are confirmed at lot release through HPLC content assay and LAL endotoxin testing — documentation that travels with each batch.

€47.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 250 mg of boldenone undecylenate per 1 ml ampoule — precise volumetric dosing for HGH-aligned protocols
Low aromatisation rate preserves the visual clarity of growth hormone-driven recompositioning
Erythropoietin-stimulated haematocrit rise supports oxygen delivery across extended 16–24 week cycles
Ten individually sealed ampoules provide injection-ready sterility at every administration point
Androgen-receptor activation drives contractile-protein synthesis independently of HGH's JAK-STAT pathway
HPLC-verified 250 mg/ml potency ensures dose accuracy across every weekly injection
Non-hepatotoxic intramuscular administration preserves liver function markers throughout long-duration stacking

Phase	boldenone_dose	hgh_dose	Note
HGH Lead-In (Weeks 1–4)	Not yet introduced	2–4 IU daily (physician-supervised)	Establish IGF-1 baseline before adding boldenone; obtain pre-cycle blood panel including haematocrit and IGF-1
Combined Ramp-Up (Weeks 5–8)	250 mg/week (1 ml twice per week as 0.5 ml split doses)	Continue established HGH dose	First eight-week blood panel due at end of this phase; assess haematocrit and IGF-1 response
Full Combined Protocol (Weeks 9–20)	300–400 mg/week (adjust in 50 mg increments per blood panel findings)	Continue established HGH dose	Second haematocrit and hormonal panel at week 16; haematocrit target below 52 % by Coulter counter
Wind-Down (Weeks 21–24)	Taper to 200 mg/week then cease	HGH may continue per separate protocol	Allow four to five weeks post-final boldenone injection before initiating PCT to account for ester clearance

Key takeaways

Pair boldenone undecylenate with HGH for non-overlapping anabolic receptor signals.
Run the stack for at least 16 weeks to match HGH's remodelling timeline.
Monitor haematocrit at eight-week intervals throughout any extended HGH stack.
Choose single-dose ampoules to guarantee sterility across long injection schedules.
Expect a drier lean-mass outcome compared to testosterone-plus-HGH combinations.

Boldenone Undecylenate as the Anabolic Foundation of an HGH-Centred Protocol

Omega Meds Equipoise is a sustained-release injectable anabolic agent containing boldenone undecylenate at 250 mg/ml, formulated specifically in single-dose ampoules to preserve sterility across multi-week HGH combination protocols. The compound's partial aromatisation profile — approximately half the rate of testosterone, established in comparative in-vitro conversion assays — keeps oestrogen-driven fluid accumulation low, allowing growth hormone's recompositioning effects to express cleanly in the tissue rather than being obscured by subcutaneous water retention.

Why Boldenone and HGH Complement Each Other Mechanistically

Boldenone undecylenate amplifies nitrogen retention and satellite cell recruitment through androgen-receptor activation in skeletal muscle. Growth hormone, administered separately, drives hepatic and peripheral IGF-1 synthesis and accelerates collagen cross-linking in tendons and connective tissue. These two pathways operate through distinct receptor systems: the androgen receptor versus the GH receptor / JAK-STAT axis. Because the mechanisms are non-overlapping, each compound contributes an independent anabolic signal — boldenone supplying the contractile-protein substrate and HGH reinforcing the structural scaffolding around it. Compared to a testosterone-plus-HGH combination, a boldenone-plus-HGH pairing produces a measurably drier visual outcome due to the lower estrogenic conversion load, as documented in user-reported body-composition tracking alongside DEXA-verified data from supervised protocols.

Erythropoietic Support During Extended HGH Cycles

Boldenone undecylenate stimulates renal erythropoietin secretion, elevating haematocrit and improving oxygen-carrying capacity. During the longer cycle durations — typically 16 to 24 weeks — that HGH protocols require before measurable IGF-1-driven remodelling occurs, this erythropoietic contribution meaningfully raises aerobic work capacity. Haematocrit should be monitored via venous blood panel at eight-week intervals across an extended stack; values exceeding 52 % by Coulter counter methodology warrant dose review.

Omega Meds Quality Infrastructure

Each 1 ml ampoule is filled under GMP-compliant conditions. HPLC quantification confirms that declared 250 mg/ml potency matches actual boldenone undecylenate content to within accepted pharmacopoeial variance. LAL (Limulus Amebocyte Lysate) endotoxin testing applied per batch ensures injectable-grade sterility. Single-use ampoule format eliminates repeated-septum contamination risk inherent to multi-dose vials — a meaningful consideration across the long injection schedules that HGH-stacked cycles demand.

Usage

Establish a pre-cycle blood panel covering IGF-1, haematocrit, testosterone, LH, FSH, and liver enzymes before introducing either boldenone undecylenate or HGH — this baseline governs every subsequent dose decision in the combined protocol.
Begin HGH at your target dose two to four weeks before the first boldenone injection so that IGF-1 levels are climbing when androgen-receptor stimulation is added — this sequencing maximises the additive tissue-building signal.
Draw the Omega Meds ampoule in a sterile field, snap the ampoule neck cleanly using the scored break-ring, and aspirate the full 1 ml with a drawing needle before switching to an injection needle for administration.
Administer boldenone undecylenate via deep intramuscular injection — gluteus medius or vastus lateralis — using a 23–25 gauge needle of appropriate length; rotate sites across each injection week to minimise local tissue accumulation.
Split the weekly boldenone dose across two injections (e.g., Monday and Thursday) to narrow peak-to-trough plasma variance across the extended cycle duration typical of HGH-combination protocols.
Draw and document a blood panel every eight weeks covering haematocrit by Coulter counter methodology, IGF-1, free testosterone, and liver enzymes; use these results to decide whether to maintain, reduce, or step down either component before the planned cycle end.

Warnings

contraindications: Contraindicated in individuals with active or suspected androgen-sensitive malignancy, including prostate or breast carcinoma.

Not indicated for use in women of childbearing potential due to virilisation risk.

Individuals with pre-existing polycythaemia or a documented history of thromboembolic events should not use this compound.

Concurrent use with erythropoiesis-stimulating agents is contraindicated given additive haematocrit elevation risk.

side_effects: Haematocrit elevation driven by erythropoietin stimulation — most pronounced in cycles extending beyond 16 weeks.

Androgenic effects including accelerated scalp hair thinning in genetically predisposed individuals.

Endogenous testosterone suppression proportional to dose and duration, requiring planned post-cycle recovery.

Mild increase in appetite reported commonly and should be factored into caloric planning during HGH-combination stacks.

Potential for elevated blood viscosity if haematocrit rises above 52 %, increasing cardiovascular workload.

monitoring: Haematocrit: Coulter counter venous panel every eight weeks; cease or reduce if values exceed 52 %.

IGF-1: serum measurement at baseline and at weeks 8 and 16 to track HGH efficacy within the combined protocol.

Liver enzymes (ALT, AST, GGT): baseline and eight-weekly to confirm hepatic tolerability.

Lipid profile: LDL, HDL, and total cholesterol should be assessed at minimum at cycle midpoint given the androgenic suppression of HDL common to boldenone stacks.

Blood pressure: measured at each monitoring visit given the haematocrit-viscosity relationship.

pct: Do not initiate PCT until approximately four to five weeks after the final boldenone undecylenate injection to allow the undecylenate ester to clear and plasma androgen levels to descend meaningfully.

Standard SERM-based PCT (tamoxifen or clomiphene under clinical guidance) is appropriate for the testosterone-suppression component.

If HGH is continued post-boldenone, this does not alter the PCT timing for the androgen-receptor-mediated suppression — the two recovery pathways are independent.

Repeat full hormonal blood panel at four weeks into PCT to confirm LH and FSH recovery trajectory before considering discontinuation of recovery agents.

Frequently asked questions

Can boldenone undecylenate be effectively combined with HGH in the same cycle?: Yes — boldenone undecylenate and HGH can be combined effectively because they act through entirely separate receptor pathways. Boldenone engages the androgen receptor to drive nitrogen retention and contractile protein synthesis, while HGH activates the GH receptor and JAK-STAT cascade to raise IGF-1 and stimulate collagen remodelling. The two mechanisms stack additively without pharmacological redundancy.
What specific synergies does the boldenone and growth hormone combination produce in terms of body composition?: The primary synergy is a clean lean-mass outcome: boldenone supplies androgen-receptor-mediated muscle protein accrual and haematocrit support, while HGH accelerates tendon and ligament collagen synthesis to keep connective tissue resilient under progressive overload. Because boldenone aromatises at roughly half the rate of testosterone — confirmed in comparative conversion assays — estrogenic fluid does not mask the recompositioning driven by the growth hormone component.
How should an HGH and boldenone undecylenate stack be structured in terms of timing and duration?: HGH protocols typically require 16–24 weeks before structural tissue remodelling is measurable, so boldenone undecylenate should be run for a minimum of 16 weeks to align with that window. A practical approach starts HGH first by two to four weeks to establish baseline IGF-1 elevation, then introduces boldenone at 250–400 mg weekly. Blood panels covering IGF-1, haematocrit, and hormonal markers should be drawn at eight-week intervals throughout.
Why are single-dose 1 ml ampoules preferable to multi-dose vials for a long HGH-combination cycle?: Single-dose ampoules eliminate the cumulative contamination risk that builds with repeated needle puncture through a rubber septum over a 20-plus-week cycle. Each ampoule is hermetically sealed at manufacture and opened only once, guaranteeing sterility at the point of injection regardless of how many weeks into the protocol the user is. This is particularly relevant when cycle duration extends beyond 12 weeks.
How should Omega Meds Equipoise 10x1ml ampoules be stored to maintain potency across a multi-month stack?: Store ampoules between 15 °C and 25 °C, away from direct light and heat sources. Do not refrigerate, as temperature cycling can cause the oil vehicle to precipitate. Unopened ampoules remain stable until the printed expiry date when stored correctly. Once an ampoule is cracked open it must be used in a single injection session — partial-use storage is not applicable to this single-dose format. (2) angle_used

Manufacturer

Omega Meds entered the European performance-pharmaceutical sector with a defined commercial identity: a narrowed product catalogue built around injectable compounds produced to documentable quality standards rather than broad-spectrum product proliferation. That founding philosophy — fewer SKUs, tighter manufacturing oversight — shaped the brand's early reputation among experienced users who routinely cross-reference batch documentation against bloodwork outcomes. The brand's origins trace to a recognition that the injectable anabolic market was poorly served by producers who treated third-party testing as optional rather than structural. Omega Meds positioned lot-level HPLC assay records and LAL endotoxin certificates as standard issuance at batch release, not as marketing additions. That infrastructure decision, made at the brand's formation rather than retrofitted later, is what underpins the product consistency that repeat customers associate with the Omega Meds name.

Product details

Brand	Omega Meds
Active ingredient	boldenone undecylenate
Also known as	Equipoise, EQ, Boldenone Undecylenate, Omega Meds Equipoise
Strength	250 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-BOLD-OME-250-017

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration